Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate

Gemcitabine is an Anticancer agent acting against several solid tumors. It requires Nucleoside Transporters for cellular uptake and deoxycytidine kinase for activation into active gemcitabine-triphosphate, which is incorporated into the DNA and RNA. However, it can also be deaminated in the plasma. The intracellular level of gemcitabine-triphosphate is affected by scheduling or by combination with Other chemotherapeutic regimens. Moreover, higher concentrations of gemcitabine-triphosphate may affect the toxicity, and possibly the clinical efficacy. As a consequence, different nucleoside analogs have been synthetized with the aim to increase the concentration of gemcitabine-triphosphate into cells. In this review, we summarize currently published evidence on pharmacological factors affecting the intracellular level of gemcitabine-triphosphate to guide future trials on the use of new nucleoside analogs.

carboplatin; cisplatin; dFdCTP; gemcitabine; nucleotides; paclitaxel; protides.